Segmental Arterial Mediolysis: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis - 19/05/18
Doi : 10.1016/j.amjmed.2018.01.057
Brett J. Carroll, MD a, Michael L. Steigner, MD b, Sarv Priya, MD b, Deepak L. Bhatt, MD, MPH a, Bradley A. Maron, MD a, c, * 
a Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass
b Department of Radiology, Non-Invasive Cardiovascular Imaging, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass
c Department of Cardiology, Boston VA Healthcare System, Boston, Mass
*Requests for reprints should be addressed to Bradley A. Maron, MD, Brigham and Women's Hospital and Harvard Medical School, Division of Cardiovascular Medicine, 77 Ave. Louis Pasteur, NRB Room 0630-N, Boston, MA 02115.Brigham and Women's Hospital and Harvard Medical SchoolDivision of Cardiovascular Medicine77 Ave. Louis Pasteur, NRB Room 0630-NBostonMA02115
Thomas J. Marrie, MD, Section Editor
Le texte complet de cet article est disponible en PDF.Plan
| Funding: BAM: National Institutes of Health (1K08HL11207-01A1, 1R56HL131787-01A1, and 1R01HL139613-01); American Heart Association (15GRNT25080016), Pulmonary Hypertension Association, Cardiovascular Medical Research and Education Fund, and Scleroderma Foundation. |
|
| Conflict of Interest: DLB discloses the following relationships. Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (Continuing Medical Education steering committees); Other: Clinical Cardiology (Deputy Editor), National Cardiovascular Data Registry-ACTION Registry Steering Committee (Chair), Veterans Affairs-Clinical Assessment Reporting and Tracking Research and Publications Committee (Chair); Research Funding: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott); Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda. BAM discloses Gilead Sci for investigator sponsored research. |
|
| Authorship: All authors had access to the data and were involved in the writing and preparation of the manuscript. |
© 2018
Publié par Elsevier Masson SAS.
Vol 131 - N° 6
P. e231-e234 - juin 2018 Retour au numéro
Article précédent
- Looking Beyond the Obvious: Eosinophilic Enterocolitis
- Elena Thampy Cherian, Hao Chi Zhang, Katie B. Guttenberg, Jamie M. Everett, Sushovan Guha
- Cervical Cancer Screening: What's New? Updates for the Busy Clinician
- Salina Zhang, Megan McNamara, Pelin Batur
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?